The UK’s Competition and Markets Authority (CMA) has consulted on a £23m ($29m) offer from Vifor Pharma in relation to the CMA’s investigation into the company’s conduct in the market for the supply of high-dose intravenous iron to the NHS. The offer is part of a wider set of
CMA receives offer from Vifor Pharma
If the offer is accepted, Vifor Pharma’s commitments will become legally binding and the CMA will not have to determine if the law was broken.